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Abstract
Background: Combining MEK inhibitors with other signalling pathway inhibitors or conventional cytotoxic drugs
represents a promising new strategy against cancer. RDEA119/BAY 869766 is a highly potent and selective MEK1/2
inhibitor undergoing phase I human clinical trials. The effects of RDEA119/BAY 869766 as a single agent and in
combination with rapamycin were studied in 3 early passage primary pancreatic cancer xenografts, OCIP19, 21, and
23, grown orthotopically.
Methods: Anti-cancer effects were determined in separate groups following chronic drug exposure. Effects on cell
cycle and downstream signalling were examined by flow cytometry and western blot, respectively. Plasma
RDEA119 concentrations were measured to monitor the drug accumulation in vivo.
Results: RDEA119/BAY 869766 alone or in combination with rapamycin showed significant growth inhibition in all
the 3 models, with a significant decrease in the percentage of cells in S-phase, accompanied by a large decrease in
bromodeoxyuridine labelling and cell cycle arrest predominantly in G1. The S6 ribosomal protein was inhibited to a
greater extent with combination treatment in all the three models. Blood plasma pharmacokinetic analyses
indicated that RDEA119 levels achieved in vivo are similar to those that produce target inhibition and cell cycle
arrest in vitro.
Conclusions: Agents targeting the ERK and mTOR pathway have anticancer activity in primary xenografts, and
these results support testing this combination in pancreatic cancer patients.
Background
The Ras-Raf-MEK-ERK signalling network has been the
subject of intense research and pharmaceutical scrutiny
to identify novel target-based approaches for cancer
treatment due to its key role in cancer progression [1].
Activating mutations of K-ras are the earliest consistently
detected abnormality in the development of pancreatic
cancer, and pancreatic cancers that spontaneously
develop in mice with genetically-modified K-ras show
similar features to those seen in patients [2]. Aberrant
expression of receptor tyrosine kinases such as EGFR and
c-Met, and loss of the ERK phosphatase DUSP6 occur
during cancer progression and activate the ERK pathway
[3]. The ERK pathway can activate genes involved in cell
growth and survival, and also regulate metabolic
processes including protein translation. An abundant
literature has shown that MEK inhibition can enhance
the effects of other signalling pathway inhibitors or
conventional cytotoxic drugs [1,4,5].
RDEA119/BAY 869766 is a selective, orally available
MEK inhibitor. It was selected for clinical development
because of its potency and favourable pharmacokinetic
profile. RDEA119 is currently undergoing phase I clini-
cal trials in late-stage cancer patients refractory or intol-
erant to other anticancer therapies [6]. We recently
reported on the effects of combined MEK and mTOR
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from pancreatic cancer cell lines [7]. However, treat-
ments that are effective against pancreatic cancer cell
line models often show much less activity in the clinic.
Primary xenografts established from patient pancreatect-
omy specimens and grown at the orthotopic site show
typical histological features of pancreatic cancer [8-10],
and therefore offer the opportunity for the near-clinical
testing of novel molecular targeted agents in a con-
trolled laboratory setting that allows detailed analysis of
the relationships between the tumour characteristics,
pharmacological effects, and anticancer effects.
In the current study, we tested the effects of RDEA119
as a single agent, or combined with rapamycin in a
panel of early-passage primary pancreatic cancer xeno-
grafts, grown orthotopically. Acute dosing strongly
inhibited tumour proliferation, and chronic treatment
produced significant growth inhibition consistent with
effects on downstream signalling pathways.
Methods
Establishment of primary pancreatic cancer xenografts
Animal experiments were carried out using protocols
approved by University Health Network Animal Welfare
Committee. The establishment of the primary pancreatic
cancer xenografts was done as previously described
[8,9,11]. Fresh pancreatectomy samples that were
superfluous to diagnostic needs were obtained from the
University Health Network Tumour Tissue Bank accord-
ing to institutional human ethical guidelines. Primary
xenografts were established at the orthotopic site of 4-to
5-week-old mice by attaching tumour fragments to the
surface of the exposed pancreas by a small incision in the
upper left abdomen under general anaesthesia. Three
orthotopic primary pancreatic cancer xenografts, desig-
nated as OCIP 19, 21, and 23, were used for these
experiments.
Drug preparation and treatment protocols
The MEK inhibitor RDEA119/BAY869766 was provided
by Ardea Biosciences, Inc. (San Diego, CA). Rapamycin
was purchased from Calbiochem (San Diego, CA). Rapa-
mycin was dissolved in DMSO at 1 mg/ml, aliquoted,
and stored at -20°C. RDEA119, which has good oral
bioavailability, was prepared freshly at 3.125 mg/ml in
10% Cremophor EL in saline, for oral gavage in vivo.
The 48 h combination therapy experiment included a
total of 12 OCIP23 tumour-bearing mice with 3 animals
randomly assigned to one of four groups: drug-vehicle
control (10% Cremophor EL in saline, oral gavage;
DMSO, i.p.), RDEA119 (6.25 mg/kg, oral gavage, b.i.d.),
rapamycin (2 mg/kg, i.p.), and RDEA119 plus rapamycin
groups (6.25 mg/kg, oral gavage, b.i.d. and 2 mg/kg, i.p.,
respectively). All mice were sacrificed 48 h after
beginning the experiment (4 h after the final dose of
RDEA119).
The chronic dosing combination therapy experiment
included 36 tumour-bearing mice for each model, with
9 animals randomly assigned to one of four groups: drug-
vehicle control, RDEA119, rapamycin, and RDEA119
plus rapamycin groups. In this experiment RDEA119 was
administered 6.25 mg/kg, oral gavage, b.i.d. 5-day on and
2-day off, rapamycin was administered 2 mg/kg i.p. once
weekly. Due to the different growth rates of these
3 models, the drug administration was initiated on Day
52, 24, and 12 after implantation in OCIP19, OCIP21,
and OCIP23, respectively. Animal body weight, and
tumour condition were recorded thrice weekly for the
duration of the study. After 2-4 weeks of treatment, the
animals were sacrificed and the tumours were harvested
immediately (4 h after the final dose of RDEA119 or/and
48 h after the final dose of rapamycin). Depending on the
subsequent analyses, all harvested tumours were cut
into pieces, either snap frozen in liquid nitrogen,
homogenized in lysis buffer as for the cell lysates, fixed in
10% formalin for 24 h and paraffin embedded.
Immunoblotting and quantification
Minced tumour pieces were homogenized in 1 ml lysis
buffer. Equivalent amounts of protein were separated on
12% SDS-PAGE gels. Proteins were transferred to poly-
vinylidene difluoride membranes (Millipore, Bedford,
MA) and probed with the appropriate antibodies. Rabbit
monoclonal antibodies against phospho-4E-BP1 (Thr37/
46) (236B4), rabbit polyclonal antibodies against phos-
pho-p44/42 MAPK (Thr202/Tyr204), phospho-S6 Ribo-
somal Protein (Ser235/236), phospho-S6 Ribosomal
Protein (Ser240/244) and antibodies directed against
their nonphosphorylated counterparts, were purchased
from Cell Signalling Technology, Inc. (Danvers, MA).
T h es e c o n d a r ya n t i b o d i e sf o rwestern blot (anti-mouse
and anti-rabbit IgG antibodies) were from Amersham
Biosciences (Buckinghamshire, United Kingdom). Mem-
branes were developed with enhanced chemilumines-
cence (ECL) Plus detection reagents and imaged using a
Typhoon™9410 system (GE Healthcare, Piscataway, NJ).
Quantification of immunoblots was performed using
ImageQuant 5.2 software by calculating an index based
on signal intensity multiplied by signal area.
Flow cytometric analysis
To study the effect of RDEA119 or/and rapamycin on
the cell cycle, snap frozen tumours were minced and
permeabilized with 0.1% Triton X-100 and stained
with 50 μg/ml propidium iodide (PI)/RNase A (1 mg/ml).
DNA histograms were analyzed using ModFit
LT™(Verity, Topsham, ME). To determine the effect of
RDEA119 or/and rapamycin administration on DNA
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kinetics, tumour-bearing mice were injected i.p. with
100 mg/kg 5-bromo-2’-deoxyuridine (BrdU) (Sigma
Chemical Co., St. Louis, MO) dissolved in PBS 30 min
before the mice were sacrificed and the tumour
removed. Single-cell suspensions from tumours were
prepared by an enzymatic technique for dual label flow
cytometry as described previously [12]. Briefly, single-
cell suspensions were fixed in 80% ethanol, denatured,
neutralized and then stained with anti-BrdU (PRBQD-
Alexa 488, Phoenix Flow Systems, Inc., San Diego, CA)
and 1 μg/ml 4’, 6-diamidino-2-phenylindole (DAPI).
BrdU labelling index was analyzed using WinList™6.0
(Verity, Topsham, ME).
Immunofluorescent, immunohistochemical staining and
image analysis
Serial sections were cut from paraffin-embedded tumour
tissue: one of these was stained with H&E for trans-
mitted light microscopy and used for selecting the
tumoural areas, on which the further image analysis was
to be done. The 48h-treatment sections were labelled
with primary antibodies against phosphorylated ERK
(Cell Signalling Technology, Inc., Danvers, MA) and
BrdU (Clone IU-4, MD5000; Caltag Laboratories, Inc.,
Burlingame, CA). Secondary antibodies used alone were
control for nonspecific background. All these sections
were counterstained with 1 μg/ml DAPI to outline the
nuclear area. p53 (DO-7, Vector Laboratories, Inc., Bur-
lingame, CA) and phosphorylated ERK (Cell Signalling
Technology, Inc., Danvers, MA) were stained for trans-
mitted light microscopy for all the chronic dosing
sections.
The analysis included the entire viable tumoural area
identified on the slide, using a scanning autostage to
create composite images of individual fields at 20 ×
magnification (2.24 mm
2) as described previously [13].
A tumoural map that included only viable tumour was
made using the H&E sections and then carefully
adjusted on the composite DAPI images. For each mar-
ker, we measured at least two variables: the intensity of
the signal (integrated absorbance) and the percentage of
positive stained area/nuclei, based on the binary images.
Analysis of plasma RDEA119 concentrations
Plasma samples were harvested 4 h after the final dose
of RDEA119 or/and 48 h after the final dose of rapamy-
cin. Plasma samples were analyzed for RDEA119 using a
liquid chromatography-tandem mass spectrometry (LC-
MS/MS) method [6]. The method involved the addition
of the internal standard ([13C6]RDEA119), protein pre-
cipitation with acetonitrile, and final analysis by high-
performance LC-MS/MS. An API 5000 triple quadruple
mass spectrometer was used to monitor the precursor!
product ion transitions of m/z 573!394 and m/z 579!400
for RDEA119 and [13C6]RDEA119 in positive electro-
spray ion mode. The calibration curves covered the
concentration range from 10 to 10,000 ng/ml.
Statistical analysis
Data from quantitative experiments are presented as
mean ± SE. Data obtained from the xenograft models
(tumour weight and animal body weight) and compari-
sons between four treatment groups were analyzed
using a repeated measure one-way ANOVA test with
Newman-Keuls multiple comparison post test. P <0 . 0 5
was considered statistically significant.
Results
Characterization of orthotopic primary pancreatic cancer
xenografts
Histological examination of the H&E sections showed
that the primary xenografts were adenocarcinomas
with features similar to the original surgical specimens.
The histological features were more complex than
those typically seen in xenografts established at the
subcutaneous site from cell lines, as has been pre-
viously noted [14]. As reported in our previous studies
[11], the OCIP19 and OCIP21 tumours are relatively
slow growing, and by histology moderately well differ-
entiated with mucin production. OCIP21 has a wild
type K-ras, whereas OCIP19 is ~60% K-ras mutant
(Codon 12). Both of these models have wild type p53.
In contrast, OCIP23 is 100% K-ras mutant (Codon 12),
p53 mutant, poorly differentiated, and more rapidly
growing. Phosphorylated ERK was readily detected in
all of the 3 models (Figure 1).
Effects of RDEA119 plus rapamycin combination on
tumour growth in orthotopic primary pancreatic cancer
xenografts
Twice daily oral administration of RDEA119 at a dose of
6.25 mg/kg was well tolerated in the tumour-bearing
mice. Loss of weight occurred in the control groups of
all the three models, which was presumably the effect of
the tumours. In the OCIP19 tumour-bearing mice, the
rapamycin treatment group significantly gained weight
(P < 0.001 vs. Control; P < 0.001 vs. Combination; P <
0.001 vs. RDEA119). There were no statistically signifi-
cant differences in the body weights of RDEA119, or
combined with rapamycin treated and control animals
at the end of treatment in any of the 3 models (Figure
2A). Because of the location of the tumour in the ortho-
topic pancreas site, the tumour size was not measured
until the end of the experiments when the animals were
killed 4 h after the final dose. Consequently, at the end
of the 2-to 3-week treatment, orthotopic tumours were
dissected free of surrounding normal tissues and
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or combination treatment of tumour models OCIP19,
21, and 23 resulted in statistically significant delay in
tumour growth when compared with vehicle-treated
controls (P < 0.001). There was significant difference
between rapamycin with RDEA119 single agent treat-
ment group (P < 0.001) or combination group (P <
0.001) in OCIP19 and OCIP23, whereas there was no
significant growth inhibition difference between
RDEA119 single agent treatment group with the combi-
nation group in all the 3 models.
Cell cycle effects in vivo
Cellular DNA content analysis by flow cytometry was
used to determine the cell cycle effects following
RDEA119, rapamycin or combination administration
(Figure 3). OCIP19 and OCIP21 are near-diploid, and
the mouse and human G1 peaks overlap, whereas
OCIP23, which is the most aggressive growing model, is
aneuploid. The percentage of S-phase in each model
was significantly decreased following the treatment of
RDEA119 or the combination with rapamycin in all the
3 models (P < 0.001).
Effects of 48 h combined inhibition of MEK and mTOR on
tumour proliferation
The OCIP23 xenograft model was selected for further
study of the 48 h treatment effects due to its genetic
features and aggressive growth. As shown in Figure 4A,
dual immunofluorescent images of phosphorylated ERK
a n dB r d Ur e v e a l e dt h a t4 8ht r e a t m e n to fR D E A 1 1 9o r
combination produced a large decrease of phosphory-
lated ERK and BrdU labelling. As shown in Figure 4B,
there was a large decrease in BrdU uptake following the
48 h treatment, indicating that RDEA119 results in the
cell cycle arrest predominantly in G1.
Figure 1 Characterization of orthotopic primary pancreatic cancer xenografts. Representative H&E and immunohistochemical staining of
p53 and phosphorylated ERK in 3 orthotopic primary pancreatic cancer xenografts. The scale bar represents 100 μm.
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downstream signalling
Representative western blots are shown in Figure 5, and
quantitative graphs in Figure 6. RDEA119, either alone
or in combination, notably dephosphorylated ERK1/2 in
OCIP19 and OCIP23 (P < 0.001, RDEA119 vs. Control,
Combination vs. Control in OCIP19; P <0 . 0 1 ,
RDEA119 vs. Control, Combination vs. Control in
OCIP23), a similar trend was also seen in OCIP21. In
OCIP19, rapamycin significantly increased ERK1/2 phos-
phorylation (P < 0.01 vs. Control), and a similar trend
w a sa l s os e e ni nt h eo t h e r 2 models. The levels of
Ser473 phosphorylated Akt were significantly increased
following the combination drug administration in
OCIP21 (P < 0.05). Treatment with rapamycin produced
decreased phosphorylation of both pairs of serine sites
on S6 ribosomal protein (Ser235/236 and Ser240/244),
consistent with previous studies [7,15]. The combination
treatment of RDEA119 and rapamycin produced the
greatest decrease in Ser235/236 and Ser240/244 phos-
phorylated S6 ribosomal protein in all the 3 models. It
should also be noted that significant decreases of total
proteins occurred in some cases following the chronic
dosing treatment.
Plasma RDEA119 concentrations in 3 xenograft models
Compound concentrations in the plasma of RDEA119
single agent or combination groups 4 h after last treat-
ment were in average 3052 vs. 3137 ng/ml, 3094 vs.
3067 ng/ml in OCIP19 and OCIP21, respectively. Lower
plasma RDEA119 concentrations in the combination
group (in average 1657 ng/ml) compared to RDEA119
single agent treatment group (in average 2833 ng/ml)
were observed in OCIP23.
Discussion
It is likely that the use of orthotopically grown early
passage primary xenografts provides a better prediction
of clinical activity compared to subcutaneous xenografts
derived from cell lines. OCIP19, 21, and 23 were
selected for this study to represent the spectrum of pan-
creatic cancer, based on their genetic features and
growth rates.
The anti-cancer effects of RDEA119 alone or in com-
bination with rapamycin were tested using twice daily
oral dosing combined with once weekly i.p. The
RDEA119 dosing is similar to the treatment schedules
commonly used in clinical trials testing novel molecular
targeted agents. The primary end points for this part of
Figure 2 Effects of RDEA119 plus rapamycin combination on tumour growth. Effects of RDEA119 plus rapamycin combination on tumour
growth in 3 orthotopic primary pancreatic cancer xenografts. A. Body weight during the chronic administration of vehicle control, single agents,
and concurrent combination. Due to the different growth rates of these 3 models, the drug administration was initiated on Day 52, 24, and 12
after implantation in OCIP19, 21, and 23, respectively. RDEA119 was administrated at 6.25 mg/kg p.o. b.i.d. (5-day on, 2-day off) and rapamycin at
2 mg/kg i.p. once weekly for 2-4 weeks; all the treatments were well tolerated. Error bars are SEM. B. Tumour weights at the completion of
chronic dose administration. Horizontal lines indicate the mean value for each group.
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Page 5 of 11Figure 3 Cell cycle effects in vivo.R e p r e s e n t a t i v es i n g l ep a r a m e t e rD N Ah i s t o g r a m s showed cell cycle effects following chronic dose
administration of 3 orthotopic primary pancreatic cancer xenografts. Percent cells in G1, S and G2/M phases are given. For OCIP23, which is
aneuploid, the values are for the cancer cells.
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of treatment period. The tumour-bearing mice were also
monitored by abdominal palpation during the treatment,
which gave a rough indication of tumour growth. No
significant spontaneous metastases were observed at the
end of the treatment. Using 6.25 mg/kg of RDEA119
twice daily for 5 days per week dose schedule or com-
bined with 2 mg/kg rapamycin once weekly dose sche-
dule, no increased toxicity relative to the drug vehicle
control group during the treatment period. In all the
three primary xenograft models, we observed a statisti-
cally significant reduction in the tumour weight relative
to the drug vehicle control group, which was consistent
with the impression obtained from the abdominal palpa-
tion that oral twice daily treatment with RDEA119 or
combined with rapamycin inhibited tumour growth.
Rapamycin also gave statistically significant growth inhi-
bition in all three models, and this effect appeared to be
additive, rather than synergistic, when the two agents
were combined. OCIP23, which is the most aggressive
growing model, showed the best response to the
RDEA119 single agent or the combination treatment.
The cell cycle effects revealed by DNA content analy-
sis and BrdU labelling were consistent with the tumour
growth inhibition effects and suggest that the ERK path-
way plays a major role driving proliferation in pancreatic
cancer. Next, the expression and constitutive phosphor-
ylation of molecules involved in the ERK and mTOR
downstream signalling pathways in pancreatic cancer
tissues were examined. Considerable inter-tumoural het-
erogeneity within the replicate samples was observed,
consistent with our previous studies [11]. There are
several mechanisms involved in the negative regulation
of Akt activity by mTORC1, the effect of S6K1 on IRS-1
downstream of IGF-1 and/or insulin receptors, or other
growth factors [16,17]. For example, in the present
study we observed activation of ERK following rapamy-
cin treatment in OCIP19 and 21, and the trend of
activation of Akt with dual MEK/mTOR inhibition in all
the 3 models, which is consistent with feedback regula-
tion of ERK and Akt [4,18]. S6 ribosomal protein
phsophorylation at Ser236/236 and Ser240/244 was
notably greater inhibited with combination treatment all
the 3 models. S6 is more likely responsive to rapamycin
rather than RDEA119 in all the 3 models, which is con-
sistent with our previous findings [7] that drug sensitiv-
ity might be affected by the tumour microenvironment
in vivo.
Induction of Bim expression with RDEA119 or com-
bined with rapamycin was also observed by western blot
in all the 3 models (data not shown), indicating that
Bim could account, at least in part, for the possible
Figure 4 Effects of 48 h combined inhibition of MEK and mTOR on tumour proliferation. Effects of 48 h combined inhibition of MEK and
mTOR on tumour proliferation. A. Dual fluorescence image analysis of BrdU and phosphorylated ERK in OCIP23 xenograft models. Representative
images (20 × single fields) of tissue sections from OCIP23 xenografts following 48 h treatment stained for phosphorylated ERK (red), BrdU (green)
and counterstained for DAPI (blue). The scale bar represents 100 μm. B. BrdU incorporation was measured by flow cytometry in OCIP23 tissue
post a 48 h exposure to 6.25 mg/kg b.i.d. RDEA119 and 2 mg/kg rapamycin.
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RDEA119 or/and 48 h after the final dose of rapamycin in the chronic dosing groups of animals were analyzed by western blot using the
indicated antibodies. Representative blots showed the effect of combined inhibition of MEK and mTOR on downstream signalling.
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loading control GAPDH was presented (n = 9 for each group). Error bars are SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
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the previous reports on the other MEK inhibitors
[19,20]. In spite of the complexity of inter-tumoural het-
erogeneity in the prediction of in vivo response, the
combination of agents targeting the ERK and mTOR
pathway has anticancer activity in primary pancreatic
cancer xenografts. This effect was seen in the K-ras and
p53 mutant OCIP23 model, as well as the less aggressive
models.
Conclusions
The current tendency is to combine molecular targeted
agents with the nucleoside analogue gemcitabine in clin-
ical trials treating patients with advanced pancreatic
cancer. However, the inhibition of BrdU uptake into
DNA during exposure to RDEA119 or its combination
with rapamycin cautions that concurrent administration
with gemcitabine might be antagonistic, and further
investigation of treatment schedules combining these
agents appears warranted. Alternatively, given the appar-
ent low toxicity of the RDEA119 + rapamycin combina-
tion, it might have palliative benefit for patients with
chemotherapy-refractory pancreatic cancer.
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